People caring for a family member with Alzheimer's disease or related dementias (ADRD) may experience a reduced quality of life due to physical, emotional, mental, and financial strain. We asked a group of providers and case managers which interventions would have the biggest impact on ADRD caregiver quality of life, and here are their top three choices. To learn more about the Precision AQ survey on Caregiving in ADRD, click here: https://lnkd.in/e7Tpqkpu
关于我们
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life changing medicines. Our global offerings include: ? Commercial Consulting & International Access Strategy ? HEOR ? Market Access Marketing ? Medical Communications & International Healthcare Communications ? Advertising, Branding, and PR ? Investor Relations and External Communications ? Data and Product Solutions ? Omnichannel Solutions Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
- 网站
-
https://www.precisionaq.com
Precision AQ的外部链接
- 所属行业
- 商务咨询服务
- 规模
- 1,001-5,000 人
- 总部
- New York,NY
- 类型
- 私人持股
- 领域
- Market access、HEOR、Medical communications、Payer marketing、Pharma advertising、Advertising & PR、Investor Relations & External Communications、Omnichannel Solutions、Payer, Provider, Patient Data Solutions、Pharma commercialization research and strategy、Patient insights、Learning & development、healthcare communications、access strategy、Pharma consulting和Pharma Launch excellence
地点
Precision AQ员工
动态
-
Ever wonder which pharma leaders are mastering the art of omnichannel engagement? Or where the industry believes AI can add value in the omnichannel space? Are you sure you’re engaging with HCPs when and how they want to be engaged? Don’t miss our live #webinar next THURSDAY (27 March) at 4PM CET and get a unique snapshot of what biopharma and its HCP and Payer audiences have been thinking and doing in the omnichannel space in 2024, as well as a look ahead at what to expect in 2025 and beyond. https://lnkd.in/ezjNnW-s #OmnichannelCustomerEngagement #MarketAccess #HealthCommunications #OmnichannelTrends #PharmaIndustry #Events
-
-
HEOR is at a crossroads—rising expectations, tighter timelines, and commercial pressures require a new approach. How can teams demonstrate their research drives real business impact? In their latest PharmaExec feature, Ross Maclean and John Graham, Pharm.D. dive into the Bookends Approach—a proven framework for aligning HEOR research with business goals without compromising scientific rigor. Learn how to apply the Bookends Approach and turn HEOR insights into action: https://lnkd.in/ecu9JEGf #HEOR #Pharma #ResearchImpact #RealWorldEvidence
-
-
Key Takeaways from #WEPA2025: What Pharma Needs to Know 1?? Affordability & Global Pricing Pressures: Governments worldwide are implementing stricter price controls, pushing for greater transparency and enforcing affordability measures. With budget constraints tightening in the US and Europe, pharma companies must rethink global pricing strategies, such as proactively exploring emerging markets like APAC and MENA. With this shift, equitable global pricing models and a clear launch market sequencing strategy to mitigate IRP challenges become imperative for a successful global launch. 2?? Rising HTA & Evidence Expectations: European HTA bodies are raising their evidence requirements for added value recognition and the impact of cross-border initiatives on evidence generation needs is unclear. APAC and MENA regions are evolving, with major pricing and reimbursement policy reforms in established markets (e.g., China, Japan) and emerging markets implementing national HTA processes (e.g., GCC, North Africa). Manufacturers must stay ahead by: ?? Adapting early to new local evidence requirements and seeking early stakeholder engagement ?? Utilizing AI-driven predictive tools to anticipate hurdles (e.g., EU JCA PICO prediction) ?? Leveraging cross-border efficiencies to streamline evidence-generation plans, approvals and pricing discussions 3?? Data-Driven Planning Is No Longer Optional: The rise of multi-indication therapies and upcoming loss of exclusivity (LOE) of multiple blockbuster drugs means that pharma companies must plan for market events earlier than ever. Analytical tools should be integrated ahead of all milestones within a product’s lifecycle to optimise launch sequencing, pricing strategy and access planning- allowing manufacturers to stay ahead of shifting market dynamics. The takeaway? Pharma companies need to think globally, act early and integrate data-driven decision-making at every step. With pricing pressures intensifying, understanding net price transparency is more critical than ever. Dive deeper into the what, how and what now of global net price transparency in our latest blog post: https://lnkd.in/e5s2nxvK #Pharma #MarketAccess #HTA #PricingStrategy
-
-
?? The AMCP 2025 Annual Meeting is in two weeks ?? Our Market Access team is packing their bags and heading to Houston for what promises to be a can’t-miss event. From strategic messaging development to engaging the right stakeholders, we’ll be sharing our industry expertise with those who want to enhance their product coverage and patient access. Book a one-on-one meeting with us between March 31st and April 3rd at and see how our team can help you. https://lnkd.in/eZjhuTUS
-
-
When market access teams find a tool that makes their jobs easier, they talk about it. This top med-tech company shared how #AccessGenius is helping them work smarter- simplifying payer insights, surfacing the most relevant information and making complex decisions easier. The best part? It delivers the answers they actually need. ?? Swipe through to see what they had to say Curious about how AccessGenius can help your team? Learn more: https://lnkd.in/gn-jJXVF #MarketAccess #PayerInsights #HealthcareStrategy #PrecisionAQ
-
Mark your calendars for April 2nd from 11:30 to 2:30 CT! ?? Our very own Erin Lopata, VP, Director of Precision AQ’s Access Experience Team, is presenting a poster at the AMCP 2025 Annual Meeting. She'll be diving into payer trends in clinical evaluation, financial management, and patient support for orphan drugs. This is a can’t-miss discussion if you’re at #AMCP2025. And be sure to book a one-on-one discussion with one of our market access experts for a personalized plan to help with patient access, omnichannel presence, and so much more: https://lnkd.in/eZjhuTUS
-
-
In our upcoming live #webinar on Thursday March 27, join our experts Ruud Kooi, Helen Laurence and Alex Grosvenor as they look at what HCP and industry #insights into engagement in 2024 can tell us about how to better connect with customers in 2025 – supported by highlights from our latest Global Trends Report. https://lnkd.in/ezjNnW-s If you are unable to make the live webinar, you are invited to register to watch it on-demand as soon as it's available. #OmnichannelCustomerEngagement #MarketAccess #HealthCommunications #OmnichannelTrends #PharmaIndustry #Events
-
-
?? Did You Know? New Orleans isn't just the birthplace of jazz, it's also the perfect backdrop for bold ideas and meaningful connections. This year, the MAPS Americas Annual Meeting (March 23-26) will bring together over 1,500 Medical Affairs professionals to shape the future of healthcare. Stop by booth 516-- Precision AQ's Medical Communications team will be there, ready to connect and chat about what's next for the industry. ?? Got a minute? Let's set up a time to share ideas and insights that matter: https://lnkd.in/euJhsTt2 #MAPS2025 #MedicalAffairs #NewOrleans #HealthcareInnovation
-
-
Navigating Oncology Market Access: What You Need to Know Getting oncology therapies to the right patients isn't just about approval- it's about understanding the real-world access landscape at leading US cancer centers. OncoGenius provides clarity on how EHR treatment plans, formularies and clinical pathways shape prescribing decisions. Here's what you can uncover: ?? Access Insights: How oncology products (yours and competitors') fit into EHR workflows, pathways and formularies at 100+ top cancer centers ?? Provider Profiles: The role of precision medicine, oral dispensing and institutional workflows in product adoption- before and after launch. ?? Biomarker & Precision Medicine Trends: How biomarker testing influences treatment selection and where access gaps exist. With these insights, pharma teams can anticipate barriers, align with provider practices and improve patient access. Learn more: https://lnkd.in/ehs9kMBx #OncologyAccess #PrecisionMedicine #OncoGenius #PharmaStrategy
-